Table 1.
Standardized reporting for correlation of cytogenetic and molecular genetic data in AML with clinical data according to Döhner et al1
t(8;21) and inv(16)/t(16;16) are frequently denoted as CBF-AML.
*Includes all AMLs with normal karyotype except for those included in the favorable subgroup.
†For most abnormalities, adequate numbers have not been studied to draw firm conclusions regarding their prognostic significance.
‡Three or more chromosome abnormalities in the absence of one of the WHO-designated recurring translocations or inversions: t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3), or t(3;3).
